News | September 15, 2022
AstraZeneca launches up-skilling program iPHARMACY
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
AstraZeneca also played a critical role in the global response to COVID-19.
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Subscribe To Our Newsletter & Stay Updated
